However, this linear disease model does not incorporate cognitive reserve, including patient-to-patient variability in cognitive impairment with comparable pathology, presence of Aβ and tau post-mortem in non-demented individuals, and the impact of neuronal compensatory mechanisms [16–19]. This evidence concerns the gene MAPT and Cognitive impairment.